Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Return on Equity: 2011-2025

Historic Return on Equity for Lineage Cell Therapeutics (LCTX) over the last 14 years, with Sep 2025 value amounting to -0.91%.

  • Lineage Cell Therapeutics' Return on Equity fell 60.00% to -0.91% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.91%, marking a year-over-year decrease of 60.00%. This contributed to the annual value of -0.26% for FY2024, which is 5.00% up from last year.
  • According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Return on Equity is -0.91%, which was down 83.32% from -0.50% recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Return on Equity high stood at -0.11% for Q3 2021, and its period low was -0.91% during Q3 2025.
  • For the 3-year period, Lineage Cell Therapeutics' Return on Equity averaged around -0.38%, with its median value being -0.33% (2023).
  • Its Return on Equity has fluctuated over the past 5 years, first spiked by 33bps in 2021, then crashed by 60bps in 2025.
  • Lineage Cell Therapeutics' Return on Equity (Quarterly) stood at -0.40% in 2021, then grew by 5bps to -0.35% in 2022, then rose by 2bps to -0.33% in 2023, then climbed by 7bps to -0.26% in 2024, then plummeted by 60bps to -0.91% in 2025.
  • Its Return on Equity stands at -0.91% for Q3 2025, versus -0.50% for Q2 2025 and -0.23% for Q1 2025.